Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
Feedback
36 remdesivir COVID-19 controlled studies, 8 RCTs
17% improvement, RR 0.83 [0.74-0.93]
c19rmd.com May 2022
Home
COVID-19 treatment studies for Remdesivir
COVID-19 treatment studies for Remdesivir
C19 studies: Remdesivir
Remdesivir
Select treatment
Select treatment
Treatments
Treatments
Antiandrogens
(meta)
Lactoferrin
(meta)
Aspirin
(meta)
Melatonin
(meta)
Bamlaniv../e..
(meta)
Metformin
(meta)
Bebtelovimab
(meta)
Molnupiravir
(meta)
Bromhexine
(meta)
N-acetylcys..
(meta)
Budesonide
(meta)
Nigella Sativa
(meta)
Cannabidiol
(meta)
Nitazoxanide
(meta)
Casirivimab/i..
(meta)
Paxlovid
(meta)
Colchicine
(meta)
Peg.. Lambda
(meta)
Conv. Plasma
(meta)
Povidone-Iod..
(meta)
Curcumin
(meta)
Probiotics
(meta)
Diet
(meta)
Proxalutamide
(meta)
Ensitrelvir
(meta)
Quercetin
(meta)
Ensovibep
(meta)
Remdesivir
(meta)
Exercise
(meta)
Sleep
(meta)
Famotidine
(meta)
Sotrovimab
(meta)
Favipiravir
(meta)
Tixagev../c..
(meta)
Fluvoxamine
(meta)
Vitamin A
(meta)
Hydroxychlor..
(meta)
Vitamin C
(meta)
Iota-carragee..
(meta)
Vitamin D
(meta)
Ivermectin
(meta)
Zinc
(meta)
Other Treatments
Global Adoption
Outcomes in COVID-19 remdesivir studies
Home
Share
Tweet
Studies
Studies
Global Adoption
Adoption
Submit Feedback
Feedback
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Outcomes in remdesivir studies. Studies show significantly increased risk of acute kidney injury.
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
0
0.5
1
1.5+
All studies
17%
36
123,330
Improvement, Studies, Patients
Relative Risk
Mortality
19%
33
122,149
Ventilation
-24%
7
32,601
ICU admission
-34%
2
2,163
Hospitalization
-39%
2
2,486
Recovery
24%
2
1,188
Viral clearance
0%
1
142
RCTs
13%
8
8,887
RCT mortality
8%
7
8,325
Peer-reviewed
12%
29
112,330
Early
76%
2
934
Late
16%
35
122,768
Remdesivir for COVID-19
c19rmd.com May 2022
Favors
remdesivir
Favors
control
after exclusions
0
0.5
1
1.5+
ALL STUDIES
MORTALITY
VENTILATION
ICU ADMISSION
HOSPITALIZATION
RECOVERY
VIRAL CLEARANCE
RCTS
RCT MORTALITY
PEER-REVIEWED
After Exclusions
ALL STUDIES
All
Early
Late
Remdesivir for COVID-19
C19RMD.COM MAY 2022
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
death
4/112
27/260
Improvement, RR [CI]
Treatment
Control
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Tau
2
= 0.06, I
2
= 11.9%, p = 0.0025
Early treatment
76%
0.24 [0.10-0.61]
6/391
42/543
76% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
death
4/48
2,510/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Solh
47%
0.53 [0.39-0.70]
death
63/219
202/424
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Mulhem
-86%
1.86 [0.21-5.24]
death
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
death
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Madan
44%
0.56 [0.33-0.95]
death
23/398
27/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Schmidt (PSM)
-509%
6.09 [2.71-13.7]
severe case
43 (n)
434 (n)
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
death
16/200
29/244
Kurniyanto
-460%
5.60 [2.32-13.5]
death
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
death
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
death
7/38
29/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Tau
2
= 0.05, I
2
= 75.6%, p = 0.0015
Late treatment
16%
0.84 [0.75-0.93]
5,909/40,614
11,810/82,154
16% improvement
All studies
17%
0.83 [0.74-0.93]
5,915/41,005
11,852/82,697
17% improvement
37 remdesivir COVID-19 studies
c19rmd.com May 2022
Tau
2
= 0.05, I
2
= 76.0%, p = 0.001
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0064
Early treatment
87%
0.13 [0.03-0.59]
2/279
15/283
87% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Tau
2
= 0.03, I
2
= 66.2%, p = 0.00027
Late treatment
17%
0.83 [0.75-0.92]
5,757/39,554
8,162/64,820
17% improvement
All studies
18%
0.82 [0.74-0.91]
5,759/39,833
8,177/65,103
18% improvement
26 remdesivir COVID-19 studies after exclusions
c19rmd.com May 2022
Tau
2
= 0.03, I
2
= 67.7%, p = 0.00021
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
4/112
27/260
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.041
Early treatment
66%
0.34 [0.12-0.96]
4/112
27/260
66% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
4/48
2,510/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
301/2,743
303/2,708
Solh
47%
0.53 [0.39-0.70]
63/219
202/424
Flisiak
49%
0.51 [0.19-1.30]
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
32 (n)
7,126 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
5/34
3/36
Mulhem
-86%
1.86 [0.21-5.24]
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
143/1,172
124/1,172
Madan
44%
0.56 [0.33-0.95]
23/398
27/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
33/286
173/852
Ader (RCT)
6%
0.94 [0.59-1.45]
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
4,441/28,855
5,499/28,855
Jamir (ICU)
8%
0.92 [0.55-1.55]
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
16/200
29/244
Kurniyanto
-460%
5.60 [2.32-13.5]
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
7/38
29/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
n/a
n/a
ICU patients
Tau
2
= 0.04, I
2
= 72.7%, p < 0.0001
Late treatment
19%
0.81 [0.73-0.90]
5,909/40,542
11,810/81,607
19% improvement
All studies
19%
0.81 [0.73-0.90]
5,913/40,654
11,837/81,867
19% improvement
34 remdesivir COVID-19 mortality results
c19rmd.com May 2022
Tau
2
= 0.04, I
2
= 72.7%, p < 0.0001
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fried
-37%
1.37 [0.81-2.30]
11/48
1,956/11,673
Improvement, RR [CI]
Treatment
Control
Ullah
-250%
3.50 [0.79-15.5]
7/30
2/30
Tsuzuki
2%
0.98 [0.91-1.07]
48/824
98/11,663
Mahajan (RCT)
-112%
2.12 [0.41-10.8]
4/34
2/36
Arch (PSM)
-68%
1.68 [1.19-2.34]
106/1,498
153/4,602
Kuno (PSM)
0%
1.00 [0.80-1.24]
140/999
140/999
Elec
11%
0.89 [0.45-1.78]
8/38
30/127
Tau
2
= 0.06, I
2
= 59.8%, p = 0.12
Late treatment
-24%
1.24 [0.95-1.61]
324/3,471
2,381/29,130
-24% improvement
All studies
-24%
1.24 [0.95-1.61]
324/3,471
2,381/29,130
-24% improvement
7 remdesivir COVID-19 mechanical ventilation results
c19rmd.com May 2022
Tau
2
= 0.06, I
2
= 59.8%, p = 0.12
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Kuno (PSM)
-17%
1.17 [1.00-1.37]
260/999
222/999
Improvement, RR [CI]
Treatment
Control
Elec
-72%
1.72 [1.11-2.66]
18/38
35/127
Tau
2
= 0.05, I
2
= 61.8%, p = 0.11
Late treatment
-34%
1.34 [0.94-1.92]
278/1,037
257/1,126
-34% improvement
All studies
-34%
1.34 [0.94-1.92]
278/1,037
257/1,126
-34% improvement
2 remdesivir COVID-19 ICU results
c19rmd.com May 2022
Tau
2
= 0.05, I
2
= 61.8%, p = 0.11
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Improvement, RR [CI]
Treatment
Control
Ohl (PSM)
-100%
2.00 [1.33-3.02]
hosp. time
1,172 (n)
1,172 (n)
Tau
2
= 0.24, I
2
= 77.6%, p = 0.41
Late treatment
-39%
1.39 [0.64-3.01]
0/1,201
0/1,285
-39% improvement
All studies
-39%
1.39 [0.64-3.01]
0/1,201
0/1,285
-39% improvement
2 remdesivir COVID-19 hospitalization results
c19rmd.com May 2022
Tau
2
= 0.24, I
2
= 77.6%, p = 0.41
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
death
4/112
27/260
Improvement, RR [CI]
Treatment
Control
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Tau
2
= 0.06, I
2
= 11.9%, p = 0.0025
Early treatment
76%
0.24 [0.10-0.61]
6/391
42/543
76% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
death
4/48
2,510/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Solh
47%
0.53 [0.39-0.70]
death
63/219
202/424
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Mulhem
-86%
1.86 [0.21-5.24]
death
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
death
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Madan
44%
0.56 [0.33-0.95]
death
23/398
27/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Schmidt (PSM)
-509%
6.09 [2.71-13.7]
severe case
43 (n)
434 (n)
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
death
16/200
29/244
Kurniyanto
-460%
5.60 [2.32-13.5]
death
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
death
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
death
7/38
29/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Tau
2
= 0.05, I
2
= 76.4%, p = 0.0016
Late treatment
16%
0.84 [0.75-0.93]
5,909/40,585
11,810/82,041
16% improvement
All studies
17%
0.83 [0.74-0.93]
5,915/40,976
11,852/82,584
17% improvement
36 remdesivir COVID-19 serious outcomes
c19rmd.com May 2022
Tau
2
= 0.05, I
2
= 76.7%, p = 0.0011
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (DB RCT)
29%
0.71 [0.37-1.37]
no recov.
43/66
45/60
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0033
Early treatment
29%
0.71 [0.37-1.37]
43/66
45/60
29% improvement
Beigel (RCT)
22%
0.78 [0.67-0.89]
no recov.
541 (n)
521 (n)
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0005
Late treatment
22%
0.78 [0.67-0.89]
0/541
0/521
22% improvement
All studies
24%
0.76 [0.67-0.85]
43/607
45/581
24% improvement
2 remdesivir COVID-19 recovery results
c19rmd.com May 2022
Tau
2
= 0.00, I
2
= 0.0%, p < 0.0001
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Goldberg
0%
1.00 [0.92-1.09]
viral+
29 (n)
113 (n)
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.98
Late treatment
0%
1.00 [0.92-1.09]
0/29
0/113
0% improvement
All studies
0%
1.00 [0.92-1.09]
0/29
0/113
0% improvement
1 remdesivir COVID-19 viral clearance result
c19rmd.com May 2022
Tau
2
= 0.00, I
2
= 0.0%, p = 0.98
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0064
Early treatment
87%
0.13 [0.03-0.59]
2/279
15/283
87% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Tau
2
= 0.00, I
2
= 0.0%, p = 0.21
Late treatment
8%
0.92 [0.81-1.05]
370/4,311
361/4,014
8% improvement
All studies
13%
0.87 [0.69-1.09]
372/4,590
376/4,297
13% improvement
8 remdesivir COVID-19 Randomized Controlled Trials
c19rmd.com May 2022
Tau
2
= 0.03, I
2
= 30.9%, p = 0.22
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wang (RCT)
-9%
1.09 [0.54-2.18]
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Spinner (RCT)
35%
0.65 [0.18-2.40]
5/384
4/200
Beigel (RCT)
27%
0.73 [0.52-1.03]
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
301/2,743
303/2,708
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
5/34
3/36
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
3/37
4/53
Ader (RCT)
6%
0.94 [0.59-1.45]
34/414
37/418
Tau
2
= 0.00, I
2
= 0.0%, p = 0.21
Late treatment
8%
0.92 [0.81-1.05]
370/4,311
361/4,014
8% improvement
All studies
8%
0.92 [0.81-1.05]
370/4,311
361/4,014
8% improvement
7 remdesivir COVID-19 RCT mortality results
c19rmd.com May 2022
Tau
2
= 0.00, I
2
= 0.0%, p = 0.21
Favors remdesivir
Favors control